Articles - Page 91 of 96 - Drugs in Context

Adherence to risk evaluation and mitigation strategies (REMS) requirements for monthly testing of liver function

Christopher M Blanchette, Anthony P Nunes, Nancy D Lin, Kathleen M Mortimer, Joshua Noone, Krishna Tangirala, Stephen Johnston, Benjamin Gutierrez

Article Type

Original Research

Published

10 Feb 2015

Risk evaluation and mitigation strategies (REMS), as mandated by the FDA for medications with the potential for harm, are increasingly incorporating rigid protocols for patient evaluation, but little is known about compliance with these programs. This study assessed adherence to liver function test (LFT) requirements included in the REMS program for bosentan and the results suggest that the program may not have adequately guaranteed adherence to monthly monitoring of LFTs.

Resource use and outcomes associated with initiation of injectable therapies for patients with type 2 diabetes mellitus

Richard Brice, Sharon Shelley, Pankaj Chaturvedi, Divina Glah, Donna Ashley, Monica Hadi

Article Type

Original Research

Published

23 Jan 2015

Management of type 2 diabetes mellitus (T2DM) often requires intervention with oral and injectable therapies. Across National Health Service (NHS) England, injectable therapies may be initiated in secondary, intermediate or primary care. This original research set out to understand resource utilization, the pathways of care, clinical outcomes, and experience of patients with T2DM
initiated on injectable therapies.

Willingness of European healthcare workers to undergo vaccination against seasonal influenza: current situation and suggestions for improvement

George Kassianos

Article Type

Case Report

Published

21 Jan 2015

Uptake of vaccination against seasonal influenza in healthcare
workers (HCWs) is, in general, low (vaccine coverage of 6–54%), as is awareness of its importance, and has been decreasing in most European Union (EU) countries in recent years. This article clarifies the current situation and makes suggestions for improvement.

Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of anti-diabetic agents

Eva M Vivian

Article Type

Review

Published

19 Dec 2014

Although several treatment options are available to reduce hyperglycemia, only about half of individuals with diagnosed diabetes mellitus (DM) achieve recommended glycemic targets. New agents that reduce blood glucose concentrations by novel mechanisms and have acceptable safety profiles are needed to improve glycemic control and reduce complications. This article reviews the evidence from clinical trials and suggests that SGLT2 inhibitors are a promising new treatment option for T2DM.

The cost of biologics for psoriasis is increasing

Judy Cheng, Steven R Feldman

Article Type

Original Research

Published

17 Dec 2014

Biologic agents have revolutionized the management of psoriasis but at a higher cost compared with “traditional” agents. Cost must be considered when evaluating management options for psoriasis. This piece of original research To estimates the annual cost of treatment of psoriasis using biologic agents and assess the trend over the past decade.